EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The effect of propranolol on gastrointestinal motility and permeability in patients with cirrhosis and significant portal hypertension

Elias Xirouchakis, Hariklia Kranidioti, Emilia Hadziyanni, Anastasia Kourikou, Christos Reppas, Maria Vertzoni, Nikolaos Papadopoulos, Melanie Deutsch, George Papatheodoridis, Spilios Manolakopoulos

BMC Gastroenterology · 2024

DOI: 10.1186/s12876-024-03483-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BMC Gastroenterology, 2024. Verfasst von Elias Xirouchakis und 9 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology-Liver-Endoscopy Unit, 2nd Department of Internal Medicine, General Hospital of Athens "Hippocration", National and Kapodistrian Univ…. Hauptthemen laut MEDLINE: Hypertension, Portal, Propranolol, Liver Cirrhosis, Gastrointestinal Motility. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The study was supported by an unrestricted grant from Hellenic Association for the Study of the Liver.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Patients with cirrhosis and portal hypertension may have alterations in intestinal barrier resulting in increased susceptibility for infections. We investigated the effect of propranolol in gastrointestinal motility, permeability and bacterial overgrowth in cirrhosis. METHODS: Patients with cirrhosis and esophageal varices were studied before and after a build-up dose of propranolol according to standard guidelines. Serum TNF-a, IL-6, IL-1b, LPS and bacterial DNA were measured before and during propranolol therapy. Oro-caecal transit time (OCTT) and bacterial overgrowth (BO) have been evaluated with H2 breath testing. Intestinal paracellular (IP), cellular passive non-carrier (ICNC), cellular passive carrier-mediated (ICCM), and gastric permeability (GP) were evaluated by measurement of lactulose, mannitol, D-xylose and sucrose respectively in urine, with high performance liquid chromatography (HPLC). RESULTS: 35 patients with cirrhosis and portal hypertension with median age was 59.6 years (range 42-86) were included in the study. Twenty one had viral hepatitis and 25 were classified as having advanced cirrhosis (Child-Pugh B: 14 or C: 11). Median dose of administrated propranolol was 40 mg/day. After 7 days propranolol treatment BO was resolved in 15 out of 16 patients (93.7%, p = 0.0001) and OCTT was reduced significantly from 180 min to 139 min (SD 58.5, difference - 4 1 min, p = 0.0001). Serum IL-6 levels were reduced in 21/35 (60%) patients from 41.1 to 19 pg/ml (p = 0.01), TNF-a in 10/35 (28.5%) patients from 10.7 to 5.6 pg/ml (p = 0.007) and LPS in 20/35 (57%) from 7.1 to 5.2 mg/L (p = 0.1). No bacterial DNA was detected in serum of all patients either baseline or under propranolol treatment. IP was significantly reduced (0.2 to 0.16, p = 0.04) whereas ICNC (p = 0.9), ICCM (p = 0.4) and GP (p = 0.7) were not affected significantly. Intestinal Permeability (PI) index (Lactulose to Mannitol ratio) was significantly reduced (0.027 to 0.02, p = 0.03). CONCLUSION: In patients with cirrhosis and portal hypertension, propranolol use is associated with reduction in BO, increase in intestinal motility and amelioration in intestinal permeability. Moreover IL-6 and LPS levels are being decreased in the majority of patients under propranolol.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypertension, PortalPropranololLiver CirrhosisGastrointestinal MotilityPermeabilityHumansMiddle AgedMaleFemaleAgedAdultAged, 80 and overEsophageal and Gastric VaricesInterleukin-6Adrenergic beta-AntagonistsTumor Necrosis Factor-alpha

Stichwörter der Autor:innen

Bacterial overgrowthCirrhosisGastrointestinal motilityGastrointestinal permeabilityPropranolol

Substanzen

PropranololInterleukin-6Adrenergic beta-AntagonistsTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Gastroenterology-Liver-Endoscopy Unit, 2nd Department of Internal Medicine, General Hospital of Athens "Hippocration", National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Gastroenterology and Hepatology, Athens Medical - P. Faliron Hospital, Athens, Greece.
  • Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Gastroenterology National, Kapodistrian University of Athens Laiko General Hospital, Athens, Greece.
  • Gastroenterology-Liver-Endoscopy Unit, 2nd Department of Internal Medicine, General Hospital of Athens "Hippocration", National and Kapodistrian University of Athens, Athens, Greece. smanolak@med.uoa.gr.
  • Department of Gastroenterology National, Kapodistrian University of Athens Laiko General Hospital, Athens, Greece. smanolak@med.uoa.gr.

Förderung

  • The study was supported by an unrestricted grant from Hellenic Association for the Study of the Liver

Zitieren

APA

Xirouchakis, E., Kranidioti, H., Hadziyanni, E., Kourikou, A., Reppas, C., Vertzoni, M., Papadopoulos, N., Deutsch, M., Papatheodoridis, G., & Manolakopoulos, S. (2024). The effect of propranolol on gastrointestinal motility and permeability in patients with cirrhosis and significant portal hypertension. BMC Gastroenterology. https://doi.org/10.1186/s12876-024-03483-6

Vancouver

Xirouchakis E, Kranidioti H, Hadziyanni E, Kourikou A, Reppas C, Vertzoni M, et al. The effect of propranolol on gastrointestinal motility and permeability in patients with cirrhosis and significant portal hypertension. BMC Gastroenterology. 2024. doi:10.1186/s12876-024-03483-6

BibTeX
@article{Xirouchakis2024,
  author = {Xirouchakis, Elias and Kranidioti, Hariklia and Hadziyanni, Emilia and Kourikou, Anastasia and Reppas, Christos and Vertzoni, Maria and Papadopoulos, Nikolaos and Deutsch, Melanie and Papatheodoridis, George and Manolakopoulos, Spilios},
  title = {The effect of propranolol on gastrointestinal motility and permeability in patients with cirrhosis and significant portal hypertension},
  journal = {BMC Gastroenterology},
  year = {2024},
  doi = {10.1186/s12876-024-03483-6}
}
Kostenlos starten →